General Information of Drug (ID: DMA8F4N)

Drug Name
ITdU Drug Info
Synonyms
3-Hydroxyandrost-5-en-17-one; Diandron, 17-Hormoforin; A-hydroxy-5-androsten-17-one; Spectrum_000661; SpecPlus_000094; Androst-5-en-17-one, 3-hydroxy-, (3.beta.)-; Spectrum3_000116; Spectrum5_000130; Spectrum4_001395; Spectrum2_000359; AC1L18FD; KBioSS_001141; KBioGR_001750; CHEMBL31399; DivK1c_006190; SPBio_000457; SCHEMBL9969169; KBio1_001134; KBio3_000872; KBio2_006277; KBio2_003709; KBio2_001141; CHEBI:95212; MolPort-003-891-893; ALBB-023670; CCG-38634; Androst-5-en-17-one, 3-hydroxy-
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
76
ChEBI ID
CHEBI:95212
TTD Drug ID
DMA8F4N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Thymidine kinase 1 (TK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Penciclovir DMOUMDV Human immunodeficiency virus infection 1C62 Approved [2]
DEOXYCYTIDINE DMYE5LJ Acute myeloid leukaemia 2A60 Approved [3]
TK-DLI DM26I8H Graft-versus-host disease 4B24 Preregistration [4]
FV-100 DMZARP1 Varicella zoster virus infection 1E91 Phase 3 [5]
Radiosensitizer gene therapy DMN1ZEU Pancreatic cancer 2C10 Phase 3 [6]
RP101 DMNIYSZ Infectious disease 1A00-CA43.1 Phase 2/3 [7]
HQK-1004 DM3WX0K Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
Rilapladib DMB9861 Arteriosclerosis BD40 Phase 1 [1]
Ad-OC-hsvTK/valacyclovir DM9GLHO Prostate cancer 2C82.0 Phase 1 [9]
Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy DMO8SGD Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Thymidine kinase 1 (TK1) TTP3QRF KITH_HUMAN Inhibitor [1]

References

1 Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1):15-22.
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9.
4 Company report (Takara Bio)
5 Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol. 2002 Feb;61(2):249-54.
6 Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8.
7 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
8 Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001 Sep;13(5):360-7.
9 Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003 Feb 10;14(3):227-41.
10 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.